Cost effectiveness of first line nivolumab plus bevacizumab and chemotherapy for advanced non squamous non small cell lung cancer.

ABSTRACT: The cost-effectiveness of nivolumab plus bevacizumab and chemotherapy for patients with advanced non-squamous non-small-cell lung-cancer (NSCLC) was uncleared yet. The current analysis aimed to evaluate the cost-effectiveness of nivolumab plus bevacizumab and chemotherapy compared with bevacizumab plus chemotherapy for patients with untreated non-squamous NSCLC in Chinese context. A partitioned survival model that simulated 3-week patients transition in 20-year time horizon was conducted to evaluate the economic value. The clinical data were obtained from TASUKI-52 trial, cost and utility values were gathered from the local charges and previously published studies. Sensitivity analyses were conducted to examine the robustness of the model results when parameters changed, subgroup analyses

SUBMITTER: Zhao S 

PROVIDER: S-EPMC12770627 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature